文献速递白血病MDS 与骨髓增殖性肿瘤

慢性粒-单核细胞白血病白血病转化中的表型亚型

Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia.
PubMed 文献 · Br J Haematol · 2023-08-22

该研究评估了189例由慢性粒-单核细胞白血病(CMML)转化而来的急性髓系白血病(AML)患者,以刻画CMML进展的表型与基因组模式。转化经单核型(Mo-AML,53%)、未成熟髓系型(My-AML,43%)或红系型(Ery-AML,2%)等不同轨迹发生,各亚型具有不同的基因组谱和克隆演化特征。My-AML中观察到低甲基化药物-维奈克拉联合治疗改善总生存(OS)和无事件生存(EFS)的趋势,而Mo-AML中未观察到。

要点

  • CMML转化AML可分为单核型(53%)、未成熟髓系型(43%)和红系型(2%)三种表型亚型。
  • Mo-AML以SRSF2、TET2和RAS通路突变共主导为特征,多经RAS通路突变克隆出现/扩增从SRSF2-TET2共突变CMML演化而来。
  • My-AML中观察到低甲基化药物-维奈克拉联合治疗改善OS和EFS的趋势,Mo-AML中未观察到。

核心结论

  • CMML向AML转化经单核型、未成熟髓系型和红系型等不同轨迹发生,各轨迹具有不同的基因组谱和克隆演化特征。
  • 这些发现为未来评估表型特异性治疗作用的研究奠定了基础。

研究设计与样本

  • 研究评估了189例由CMML转化而来的AML患者队列。

主要发现

  • Mo-AML占53%,以单核母细胞和幼单核细胞扩增为特征(CD34、CD117低表达;CD14、CD33、CD56和CD64高表达),由SRSF2、TET2和RAS通路突变共主导定义,更可能经RAS通路突变克隆的出现/扩增从SRSF2-TET2共突变CMML演化而来。
  • My-AML占43%,以未成熟髓系原始细胞扩增为特征(CD34、CD38、CD117高频率;CD14、CD64和CD56表达低频率),较少呈现SRSF2-TET2共突变或RAS通路突变,CEBPA突变频率较高。
  • Ery-AML占2%,由复杂核型和TP53突变定义。
  • My-AML中观察到低甲基化药物-维奈克拉联合治疗改善OS和EFS的趋势,Mo-AML中未观察到。

关键数值与推荐

  • Mo-AML:53%,低CD34、CD117表达,高CD14、CD33、CD56和CD64表达。
  • My-AML:43%,CD34、CD38、CD117高频率,CD14、CD64和CD56表达低频率。
  • Ery-AML:2%,复杂核型和TP53突变。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic myelomonocytic leukaemia (CMML) is a haematological disorder with high risk of transformation to acute myeloid leukaemia (AML). To characterize the phenotypic and genomic patterns of CMML progression, we evaluated a cohort of 189 patients with AML evolving from CMML. We found that transformation occurs through distinct trajectories characterized by genomic profiles and clonal evolution: monocytic (Mo-AML, 53%), immature myeloid (My-AML, 43%) or erythroid (Ery-AML, 2%). Mo-AML, characterized by expansion of monoblasts and promonocytes (low CD34, CD117 expression; high CD14, CD33, CD56 and CD64 expression), were defined by SRSF2, TET2 and RAS pathway mutation co-dominance and were more likely to evolve from SRSF2-TET2 co-mutant CMML through emergence/expansion of RAS pathway mutant clones. Conversely, My-AML, characterized by expansion of immature myeloid blasts (high frequency of CD34, CD38, CD117; low frequency of CD14, CD64 and CD56 expression) were less likely to exhibit SRSF2-TET2 co-mutations or RAS pathway mutations and had higher frequency of CEBPA mutations. Ery-AML was defined by complex karyotypes and TP53 mutations. A trend towards improved OS and EFS with hypomethylating agent-venetoclax combination was observed in My-AML, but not Mo-AML. These findings define distinct progression of CMML and set the basis for future studies evaluating the role of phenotype-specific therapeutics.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Montalban-Bravo G, Kanagal-Shamanna R, Li Z, et al. Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia. Br J Haematol. 2023. PMID: 37608562. doi:10.1111/bjh.19060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。